Scholarlink

Background <p>Chromophobe renal cell carcinoma (chRCC) represents a distinct histological subtype of kidney cancer. While typically characterized by an indolent clinical course, it presents significant management challenges in advanced or late-stage disease.</p> Main body of the abstract <p>This review presents current evidence regarding chRCC histopathology, emerging biomarkers, and proposed grading systems. We comprehensively analyze the molecular landscape, highlighting TP53 and PTEN mutations alongside characteristic chromosomal losses, while evaluating the role of epigenetic modifications and the immune microenvironment. Crucially, the paper details the mechanisms through which mitochondrial dysfunction and metabolic reprogramming drive chRCC pathogenesis. By assessing contemporary clinical trials, this work underscores the necessity for novel therapeutic interventions and the collection of large-scale prospective data to address current gaps in treatment.</p> Conclusion <p>A precision oncology framework for chRCC should prioritize reproducible diagnosis, cautious biomarker validation, and prospective rare-tumor trials to refine risk stratification and management.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Chromophobe renal cell carcinoma: addressing the translational gap toward precision oncology for advanced disease

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月28日

查看全文
  • Xiwen Lei,
  • Rui Dong,
  • Lijuan Yin,
  • Zhenjie Wu,
  • Linhui Wang,
  • Miaoxia He

摘要

Background

Chromophobe renal cell carcinoma (chRCC) represents a distinct histological subtype of kidney cancer. While typically characterized by an indolent clinical course, it presents significant management challenges in advanced or late-stage disease.

Main body of the abstract

This review presents current evidence regarding chRCC histopathology, emerging biomarkers, and proposed grading systems. We comprehensively analyze the molecular landscape, highlighting TP53 and PTEN mutations alongside characteristic chromosomal losses, while evaluating the role of epigenetic modifications and the immune microenvironment. Crucially, the paper details the mechanisms through which mitochondrial dysfunction and metabolic reprogramming drive chRCC pathogenesis. By assessing contemporary clinical trials, this work underscores the necessity for novel therapeutic interventions and the collection of large-scale prospective data to address current gaps in treatment.

Conclusion

A precision oncology framework for chRCC should prioritize reproducible diagnosis, cautious biomarker validation, and prospective rare-tumor trials to refine risk stratification and management.